Emory University Decreased Its Amicus Therapeutics (FOLD) Holding as Market Valuation Rose; Harber Asset Management Decreased Dollar Gen New (DG) Stake by $3.94 Million

February 15, 2018 - By Stephen Andrade

Raymond J. Harbert decreased its stake in Dollar Gen Corp New (DG) by 39.48% based on its latest 2017Q3 regulatory filing with the SEC. Harber Asset Management Llc sold 48,651 shares as the company’s stock declined 7.36% while stock markets rallied. The hedge fund run by Raymond J. Harbert held 74,567 shares of the department and specialty retail stores company at the end of 2017Q3, valued at $6.04M, down from 123,218 at the end of the previous reported quarter. Harber Asset Management Llc who had been investing in Dollar Gen Corp New for a number of months, seems to be less bullish one the $26.37 billion market cap company. The stock increased 0.44% or $0.425 during the last trading session, reaching $97.095. About 955,099 shares traded. Dollar General Corporation (NYSE:DG) has declined 12.26% since February 15, 2017 and is downtrending. It has underperformed by 28.96% the S&P500.

Emory University decreased its stake in Amicus Therapeutics Inc (FOLD) by 34.53% based on its latest 2017Q3 regulatory filing with the SEC. Emory University sold 69,878 shares as the company’s stock rose 23.92% with the market. The institutional investor held 132,479 shares of the health care company at the end of 2017Q3, valued at $2.00M, down from 202,357 at the end of the previous reported quarter. Emory University who had been investing in Amicus Therapeutics Inc for a number of months, seems to be less bullish one the $2.65 billion market cap company. The stock increased 1.47% or $0.23 during the last trading session, reaching $15.91. About 2.48 million shares traded. Amicus Therapeutics, Inc. (NASDAQ:FOLD) has risen 12.45% since February 15, 2017 and is uptrending. It has underperformed by 4.25% the S&P500.

Since October 12, 2017, it had 0 insider purchases, and 16 selling transactions for $11.04 million activity. Shares for $300,002 were sold by HAYDEN DONALD J JR on Tuesday, January 2. $1.06 million worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) shares were sold by Crowley John F. Andrews Kurt J. also sold $147,191 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) shares. Another trade for 50,194 shares valued at $715,360 was made by Do Hung on Thursday, October 12. The insider Quimi Daphne sold 7,000 shares worth $99,740. RAAB MICHAEL sold $142,534 worth of stock.

Among 9 analysts covering Amicus Therapeutics (NASDAQ:FOLD), 8 have Buy rating, 0 Sell and 1 Hold. Therefore 89% are positive. Amicus Therapeutics had 22 analyst reports since August 18, 2015 according to SRatingsIntel. The firm earned “Neutral” rating on Wednesday, March 30 by Goldman Sachs. On Tuesday, July 11 the stock rating was maintained by Cowen & Co with “Buy”. The stock of Amicus Therapeutics, Inc. (NASDAQ:FOLD) has “Overweight” rating given on Tuesday, September 8 by JP Morgan. Robert W. Baird upgraded the stock to “Outperform” rating in Tuesday, January 24 report. Chardan Capital Markets downgraded it to “Neutral” rating and $17 target in Wednesday, September 16 report. Chardan Capital Markets upgraded the shares of FOLD in report on Monday, October 5 to “Buy” rating. On Tuesday, August 18 the stock rating was downgraded by Zacks to “Buy”. Leerink Swann maintained Amicus Therapeutics, Inc. (NASDAQ:FOLD) on Monday, August 31 with “Buy” rating. Cowen & Co maintained Amicus Therapeutics, Inc. (NASDAQ:FOLD) on Sunday, June 25 with “Buy” rating. The rating was maintained by Leerink Swann on Monday, October 5 with “Outperform”.

Analysts await Amicus Therapeutics, Inc. (NASDAQ:FOLD) to report earnings on March, 7. They expect $-0.30 earnings per share, up 6.25% or $0.02 from last year’s $-0.32 per share. After $-0.41 actual earnings per share reported by Amicus Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -26.83% EPS growth.

Investors sentiment increased to 2.33 in 2017 Q3. Its up 1.10, from 1.23 in 2017Q2. It improved, as 16 investors sold FOLD shares while 32 reduced holdings. 52 funds opened positions while 60 raised stakes. 192.70 million shares or 14.18% more from 168.77 million shares in 2017Q2 were reported. Palo Alto Invsts Lc holds 7.42M shares. Northern Tru owns 1.98M shares for 0.01% of their portfolio. Credit Suisse Ag reported 913,742 shares. Commonwealth Equity Serv reported 30,561 shares stake. Swiss Bankshares owns 240,300 shares or 0% of their US portfolio. 28,063 were reported by Hightower Lc. Group One Trading Lp stated it has 281,330 shares or 0.04% of all its holdings. Pacad Investment Limited reported 32,000 shares. 200,000 are held by Ghost Tree Cap Lc. Quantitative Systematic Strategies Llc holds 11,117 shares or 0.04% of its portfolio. Engineers Gate Manager Lp holds 0.01% or 10,300 shares in its portfolio. Parametric Assocs Limited Liability Corp holds 0% or 72,923 shares in its portfolio. Amalgamated Bancorp accumulated 0.01% or 21,017 shares. Alliancebernstein Lp invested in 337,826 shares. Grp reported 109,628 shares.

Emory University, which manages about $126.35M US Long portfolio, upped its stake in Seagate Technology Plc (NASDAQ:STX) by 13,977 shares to 50,550 shares, valued at $1.68M in 2017Q3, according to the filing. It also increased its holding in Ra Pharmaceuticals Inc by 48,940 shares in the quarter, for a total of 112,084 shares, and has risen its stake in Zogenix Inc.

Analysts await Dollar General Corporation (NYSE:DG) to report earnings on March, 15. They expect $1.45 EPS, down 2.68% or $0.04 from last year’s $1.49 per share. DG’s profit will be $393.78 million for 16.74 P/E if the $1.45 EPS becomes a reality. After $0.98 actual EPS reported by Dollar General Corporation for the previous quarter, Wall Street now forecasts 47.96% EPS growth.

Harber Asset Management Llc, which manages about $271.95M US Long portfolio, upped its stake in Qualcomm Inc (Call) by 589 shares to 4,481 shares, valued at $2.80M in 2017Q3, according to the filing. It also increased its holding in Liquidity Services Inc (NASDAQ:LQDT) by 451,017 shares in the quarter, for a total of 1.00 million shares, and has risen its stake in Nutanix Inc.

Among 30 analysts covering Dollar General Corp. (NYSE:DG), 17 have Buy rating, 2 Sell and 11 Hold. Therefore 57% are positive. Dollar General Corp. had 101 analyst reports since August 13, 2015 according to SRatingsIntel. On Tuesday, June 6 the stock rating was maintained by Morgan Stanley with “Buy”. On Wednesday, September 7 the stock rating was downgraded by Wolfe Research to “Underperform”. The stock of Dollar General Corporation (NYSE:DG) has “Buy” rating given on Thursday, November 16 by Deutsche Bank. The firm has “Buy” rating given on Friday, September 29 by Piper Jaffray. RBC Capital Markets maintained Dollar General Corporation (NYSE:DG) on Wednesday, December 2 with “Outperform” rating. As per Friday, November 10, the company rating was maintained by RBC Capital Markets. The rating was maintained by Deutsche Bank on Wednesday, October 7 with “Buy”. Deutsche Bank maintained it with “Buy” rating and $95 target in Friday, May 27 report. The company was maintained on Friday, August 25 by Bank of America. The firm has “Overweight” rating given on Tuesday, November 3 by Piper Jaffray.

Since September 12, 2017, it had 0 insider buys, and 5 sales for $3.04 million activity. Shares for $683,092 were sold by Kindy Michael J on Thursday, December 14. ELLIOTT ANITA C also sold $186,747 worth of Dollar General Corporation (NYSE:DG) on Monday, December 18. Shares for $251,895 were sold by TAYLOR RHONDA on Tuesday, December 12.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts